余文穎，1984年6月生。博士、副研究員、博士生導師。美國藥學會會員，美國化學會會員。現任教於中國藥科大學。
基本介紹
- 中文名：余文穎
- 國籍：中國
- 民族：漢族
- 出生日期：1984年6月
- 畢業院校：中國藥科大學、俄亥俄州立大學
- 學位/學歷：博士
- 專業方向：藥物化學
- 職稱：副研究員
人物經歷,研究方向,主要成就,主持課題,學術成果,
人物經歷
1984年6月生。
2006年免試推薦為中國藥科大學藥物化學碩士研究生。
2008年獲理學碩士學位。同年獲美國俄亥俄州立大學（The Ohio State University）藥學院全額獎學金資助留學。
2013年獲俄亥俄州立大學藥物化學博士學位（PhD.），並獲得JACK. L. BEAL優秀博士生獎學金。
2013年底作為海外人才引進於中國藥科大學藥物科學研究院國家重點實驗室。
2016年晉升為特聘副研究員；2017年晉升為副研究員。
研究方向
1. 計算機輔助藥物設計（CADD）新方法的設計和研究；
3. 基於活性天然化合物的合成方法研究和藥物研究；
4. 針對IL-6/JAK/STAT信號通路的藥物研究。
主要成就
從事科研工作以來，緊密結合藥物化學、計算化學、合成化學、生物統計學、藥理學等交叉專業背景的優勢，設計和發現了針對腫瘤靶點“蛋白-蛋白”相互作用的藥物活性分子，取得了一系列標誌性、創新性的重要研究成果。其中在藥物化學領域一區雜誌Journal of Medicinal Chemistry等發表多篇文章。授權美國專利和世界專利各1項。
主持課題
作為課題負責人主持了國家自然科學基金面上項目一項，
江蘇省自然科學基金優秀青年項目一項，
國家自然科學基金青年項目一項，
江蘇省自然科學基金青年項目一項，
留學回國人員擇優資助項目一項等，經費總計逾百萬元。
作為主要參與人參加了國家自然科學基金重點項目等多項基金。
2014年入選江蘇省雙創計畫“雙創博士”。
2015年指導的大創項目被評為國家級優秀項目。
學術成果
余文穎
1.Wenying Yu, Chenglong Li, Wenda Zhang, Shanshan Li, Jia-yuh Lin, Keqin Yu, Mu Liu, Lei Yang, Jianguang Luo, Yijun Chen, Hongbin Sun, and Lingyi Kong*, Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking, Journal of Medicinal Chemistry, 2017, 60, 2718-2731. (IF:6.3)
2.Wenying Yu, Hui Xiao, Jiayuh Lin, Chenglong Li, Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design, Journal of Medicinal Chemistry, 2013, 56, 4402−4412 (IF: 5.5)
3.Wenda Zhang, Feiyan Liu, Chao Zhang, Jianguang Luo, Jun Luo, Wenying Yu**, and Lingyi Kong*, Near-Infrared Fluorescent Probe with Remarkable Large Stokes Shift and Favorable Water Solubility for Real-Time Tracking Leucine Aminopeptidase in Living Cells and In Vivo,Analytical Chemistry,2017, 89, 12319−12326. (IF: 6.2)
4.Jianpeng Guo, Wenying Yu**, Guiping Cai, Wenda Zhang, Shanshan Li, Jiawen Zhu, Dongmei Song, Lingyi Kong*. Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors, European Journal of Medicinal Chemistry, 2018, 151, 752-764. (IF: 4.8)
5.Wenda Zhang, Ting Ma, Shanshan Li, Yanwei Yang, Jianpeng Guo, Wenying Yu**, Lingyi Kong*, Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules, European Journal of Medicinal Chemistry, 2017, 125, 538-550. (IF: 4.8)
6.Shanshan Li, Wenda Zhang, Yanwei Yang, Ting Ma, Jianpeng Guo, Shanshan Wang, Wenying Yu**, Lingyi Kong*, Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein, European Journal of Medicinal Chemistry, 2016, 124, 1006-1018. (IF: 4.5)
7.Wenda Zhang, Jianpeng Guo, Shanshan Li, Ting Ma, Dingqiao Xu, Chao Han, Feiyan Liu, Wenying Yu**, Lingyi Kong*, Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy, Scientific Reports, 2017, 7:46352. (IF: 4.3)
8.Wenying Yu, Chenglong Li, Regioselective one-pot C-N coupling of substituted naphthoquinones: selective intramolecular ring fusion of sulfonamides, Tetrahedron, 2014, 70, 459-464. (IF: 2.6)
9.Wenying Yu, Chenglong Li, 4-Nitrophenyl N-(2-sulfamoylphenyl)-carbamate，Acta Crystallographica Section E, 2013, E69, o355
10.余文穎, 張奕華, 賴宜生, 接振旺, 張玉彬, 彭司勛, 一氧化氮供體型雙水楊酸酯衍生物的合成及降血糖活性, 中國藥科大學學報, 2008, 39, 4, 301-305
11.Chongqiang Zhao, Wenlong Wang, Wenying Yu, David Jou, Yina Wang, Haiyan Ma, Hui Xiao, Hua Qin, Cuntai Zhang, Jiagao Lu, Sheng Li, Chenglong Li, Jiayuh Lin, Li Lin, A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration colon and liver cancer cells, Oncotarget, 2016 (IF: 5.2)
12.Jin-Fang Xu, Hui-Jun Zhao, Xiao-Bing Wang, Zhong-Rui Li, Jun Luo, Ming-Hua Yang, Lei Yang, Wen-Ying Yu, He-Quan Yao, Jian-Guang Luo*, Ling-Yi Kong*, (±)-Melicolones A and B, rearranged prenylated acetophenone stereoisomers with an unusual 9-oxatricyclo[3.2.1.1]nonane core from the leaves of Melicope ptelefolia, Organic Letters, 2015, 17, 1, 146-149. (IF: 6.7)
13.Yan Liu, Aiguo Liu, Zhenghu Xu, Wenying Yu, Hong Wang, Chenglong Li, Jiayuh Lin*,XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells, Apoptosis, 2011, 16, 5, 502-10. (IF: 4.8)
14.Hui Xiao, Hemant Kumar Bid, David Jou, Xiaojuan Wu, Wenying Yu, Chenglong Li, Peter J. Houghton, Jiayuh Lin*, A Novel Small Molecular STAT3 Inhibitor, LY5, Inhibits Cell Viability, Cell Migration, and Angiogenesis in Medulloblastoma Cells, The Journal of Biological Chemistry, 2015, 290, 3418-3429. (IF: 4.3)
15.Sai-Sai Xie, Xiaobing Wang, Neng Jiang, Wenying Yu, Kelvin D.G. Wang, Jin-Shuai Lan, Zhong-Rui Li, Ling-Yi Kong*, Multi-target tacrine-coumarin hybrids: Cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease, European Journal of Medicinal Chemistry, 2015, 95, 5, 153-165. (IF: 3.9)
16.Aiguo Liu, Yan Liu, Zhenghu Xu, Wenying Yu, Hong Wang, Chenglong Li, Jiayuh Lin*, Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells, Cancer science, 2011, 102, 7, 1381-1387
17.Yang Li, Xuliang Wang, Rong Fu, Wenying Yu, Xiaoli Wang, Yisheng Lai, Sixun Peng, Yihua Zhang*, Synthesis and evaluation of nitric oxide-releasing derivatives of 3-n-butylphthalide as anti-platelet agents, Bioorganic & Medicinal Chemistry Letters, 2011, 21, 14, 4210-4214. (IF: 2.6)
18.Zi-Chen Xu, Xiao-Bing Wang, Wen-Ying Yu, Sai-Sai Xie, Su-Yi Li, Ling-Yi Kong*, Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease, Bioorganic & Medicinal Chemistry Letters, 2014, 24, 10, 2368-237. (IF: 2.4)
